John A. Martens

Formulation Scientist — Aging Health Sciences

John A. Martens is the formulation architect behind MaculaPM® — the scientist responsible for translating cutting-edge retinal research into a stable, bioavailable supplement that works the way the science intends.

With 35 years as a corporate scientist at 3M Corporation and degrees in both Chemical Engineering and Chemistry, John brings a rare combination of precision engineering and deep materials science to nutraceutical development. His career has spanned pharmaceutical, nutraceutical, and biomedical product development, with particular focus on formulations related to eye health.

Turning research findings into a formulation is not straightforward — it requires navigating ingredient stability, bioavailability, dosing strategy, and delivery form. John’s role ensures that every ingredient in MaculaPM® is present in the right form, at the right dose, in a capsule designed for consistent nightly use.

His industrial science background — honed across decades at one of the world’s most respected research-driven companies — brings a level of formulation rigor rarely found in the supplement industry.

Credentials & Background

  • Degrees in Chemical Engineering and Chemistry
  • 35 years as Corporate Scientist, 3M Corporation
  • Decades of experience in nutraceutical, pharmaceutical, and biomedical product development
  • Specialization in eye disease-related formulations

These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

A Closer Look at Retinal Biology

The retina depends on a critical support layer called the Retinal Pigment Epithelium (RPE). RPE cells produce melanin pigment, and a byproduct of that synthesis process is L-DOPA. As we age, melanin synthesis in the RPE slows, reducing natural L-DOPA production. This reduction appears to be more pronounced in lightly pigmented individuals and typically accelerates after age 60.

In the eye, L-DOPA functions as a signaling molecule that interacts with GPR143, a G-protein coupled receptor. Research indicates that this signaling relationship influences the regulation of VEGF and supports the activity of PEDF, a protein naturally secreted by the RPE that scientific literature associates with neuroprotective activity, photoreceptor support, and healthy management of blood vessel growth.

Melatonin contributes to the circadian regulation of these processes. Because both L-DOPA and melatonin production decline naturally with age, MaculaPM® is designed to provide dietary support for these pathways during a period when the eye's own production may be diminished.

MaculaPM® Nighttime Eye Support

$57.99

Science-based · Doctor-derived · University-researched
MaculaPM® — Nighttime eye support formulated around retinal signaling and circadian biology.

While you sleep, the eye performs its most important maintenance and renewal processes. MaculaPM® is a once-nightly formula built around this biology — combining L-DOPA, melatonin, and key macular nutrients selected for their roles in retinal signaling, nighttime circadian function, and macular support.†

Developed by researchers at the University of Arizona. Backed by US patents 11,969,401 and 9,173,862. 60 capsules — 30-day supply.

What's inside — 6 evidence-based ingredients

L-DOPA (from Mucuna pruriens seed extract) — 100 mg
Supports retinal signaling through the GPR143 receptor in the retinal pigment epithelium. Involved in both pigment biology and retinal maintenance.

Melatonin — 5 mg
A naturally occurring hormone that regulates circadian rhythm, aligning the formula with the eye's overnight maintenance and renewal cycle.

Lutein (from Tagetes erecta L. flower) — 5 mg
Concentrates in the macula to help filter high-energy blue light and support macular pigment optical density. Included at doses studied in AREDS2 clinical trials.†

Zeaxanthin (from Tagetes erecta L. flower) — 2 mg
Works alongside lutein in the fovea to support central vision and macular pigment. Also studied in AREDS2 clinical trials.†

Vitamin C (as Ascorbic Acid) — 100 mg
An antioxidant that helps support the body's natural defenses against oxidative stress in retinal cells. Included in the AREDS clinical formula.

Vitamin E (as D-Alpha Tocopheryl Acid Succinate) — 35 mg
Supports antioxidant defense in photoreceptor cell membranes and retinal tissue. Part of the AREDS and AREDS2 clinical trial evidence base.

These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.